



## **Flarin Holdings appoints CTH to drive globalisation of the world's first lipid formulated ibuprofen**

Flarin Holdings Limited (FHL), trading through its subsidiary Infirst Limited, today announces that it has appointed Capel Thompson & Homer LLP (CTH) as advisor to assist in seeking a licensing partner for its patented lipid NSAID technology in the USA and other geographies.

FHL was originally demerged from Infirst Healthcare Limited in 2019 in order to provide greater focus on the rapid commercialisation of the technology. It has successfully marketed the world's first lipid formulated ibuprofen in the UK under the brand name Flarin. Flarin has seen rapid expansion of both its P and GSL formats in the UK market with distribution in all major pharmacy and supermarket chains and is the fastest-growing analgesic brand in the UK market.

The next step for FHL in taking the lipid NSAID technology to global markets is to seek entry to the US market for which regulatory procedures are already underway. CTH have been appointed to secure a partner to bring a lipid formulated ibuprofen product to the US market.

### **About Flarin Holdings**

Flarin Holdings was demerged from Infirst Healthcare Limited in 2019 in order to focus on commercialising Flarin's unique lipid formulation of ibuprofen.

### **About Flarin Lipid Formulation Technology**

Flarin is a unique and patent protected lipid formulated ibuprofen which at a dose of 1200 mg/day has been shown to be as effective as 2400mg/day of standard liquid ibuprofen capsules in patients with acute joint pain [1].

### **About CTH**

CTH is an international provider of high level, independent corporate finance advice and transaction support to firms in the health and life sciences industries. CTH provides advice on corporate partnering (including licensing and alliances) and M&A, as well as creating and executing financial transactions. CTH clients comprise established diagnostics, pharma, biotech, medtech, consumer-health, and digital-health companies.

Media enquiries:

FHL: philip.lindsell@infirst.co.uk +44 204 526 0241

CTH: pthompson@capelthompson.co.uk +44 207 808 0313

---

1 Bierma- Zeinstra SMA, Conaghan PG, Brew J et al. Osteoarthr Cartil: 2017 25;  
12: 1942–1951 Open Access: <http://dx.doi.org/10.1016/j.joca.2017.09.002> Accessed  
at: [http://www.oarsijournal.com/article/S1063-4584\(17\)31197-4/fulltext](http://www.oarsijournal.com/article/S1063-4584(17)31197-4/fulltext)

[www.flarin.co.uk](http://www.flarin.co.uk)

<https://www.linkedin.com/company/flarin/>

Date of preparation: October 2022